Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07892300
EARLY_PHASE1

Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

Sponsor: Oliver Jonas

View on ClinicalTrials.gov

Summary

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma. The name of the intervention(s) involved in this study are: Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.

Official title: Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-10-30

Completion Date

2031-10-30

Last Updated

2026-10-23

Healthy Volunteers

No

Interventions

DRUG

Implantable Micro- drug delivery Microdevice (IMD)

Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib.